| Year |
Citation |
Score |
| 2018 |
Loyet KM, Hass PE, Sandoval W, Morando A, Liu P, Shatz W, Dickmann L, Kenrick M, Good J, Davancaze T, Morimoto AM, Kelley RF, Scheer JM. In Vivo Stability Profiles of Anti-Factor D Molecules Support Long-Acting Delivery Approaches. Molecular Pharmaceutics. PMID 30444371 DOI: 10.1021/Acs.Molpharmaceut.8B00871 |
0.31 |
|
| 2017 |
Tesar D, Luoma J, Wyatt EA, Shi C, Shatz W, Hass PE, Mathieu M, Yi L, Corn JE, Maass KF, Wang K, Dion MZ, Andersen N, Loyet KM, Campagne MVL, ... ... Dickmann L, et al. Protein engineering to increase the potential of a therapeutic antibody Fab for long-acting delivery to the eye. Mabs. 0. PMID 28854082 DOI: 10.1080/19420862.2017.1372078 |
0.317 |
|
| 2016 |
Foti RS, Isoherranen N, Zelter A, Dickmann LJ, Buttrick BR, Diaz P, Douguet D. Identification of Tazarotenic Acid as the First Xenobiotic Substrate of Human Retinoic Acid Hydroxylase CYP26A1 and CYP26B1. The Journal of Pharmacology and Experimental Therapeutics. PMID 26937021 DOI: 10.1124/Jpet.116.232637 |
0.441 |
|
| 2015 |
Wei X, Kenny JR, Dickmann L, Maciuca R, Looney C, Tang MT. Assessment of disease related therapeutic protein drug-drug interaction for etrolizumab in patients with moderately to severely active ulcerative colitis. Journal of Clinical Pharmacology. PMID 26412221 DOI: 10.1002/Jcph.649 |
0.341 |
|
| 2013 |
Evers R, Dallas S, Dickmann LJ, Fahmi OA, Kenny JR, Kraynov E, Nguyen T, Patel AH, Slatter JG, Zhang L. Critical review of preclinical approaches to investigate cytochrome p450-mediated therapeutic protein drug-drug interactions and recommendations for best practices: a white paper. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 41: 1598-609. PMID 23792813 DOI: 10.1124/Dmd.113.052225 |
0.332 |
|
| 2013 |
Konopnicki CM, Dickmann LJ, Tracy JM, Tukey RH, Wienkers LC, Foti RS. Evaluation of UGT protein interactions in human hepatocytes: effect of siRNA down regulation of UGT1A9 and UGT2B7 on propofol glucuronidation in human hepatocytes. Archives of Biochemistry and Biophysics. 535: 143-9. PMID 23562620 DOI: 10.1016/J.Abb.2013.03.012 |
0.356 |
|
| 2013 |
Wang Z, Lin YS, Dickmann LJ, Poulton EJ, Eaton DL, Lampe JW, Shen DD, Davis CL, Shuhart MC, Thummel KE. Enhancement of hepatic 4-hydroxylation of 25-hydroxyvitamin D3 through CYP3A4 induction in vitro and in vivo: implications for drug-induced osteomalacia. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 28: 1101-16. PMID 23212742 DOI: 10.1002/Jbmr.1839 |
0.342 |
|
| 2012 |
Dickmann LJ, VandenBrink BM, Lin YS. In vitro hepatotoxicity and cytochrome P450 induction and inhibition characteristics of carnosic acid, a dietary supplement with antiadipogenic properties. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 40: 1263-7. PMID 22531045 DOI: 10.1124/Dmd.112.044909 |
0.4 |
|
| 2012 |
Wang Z, Lin YS, Zheng XE, Senn T, Hashizume T, Scian M, Dickmann LJ, Nelson SD, Baillie TA, Hebert MF, Blough D, Davis CL, Thummel KE. An inducible cytochrome P450 3A4-dependent vitamin D catabolic pathway. Molecular Pharmacology. 81: 498-509. PMID 22205755 DOI: 10.1124/Mol.111.076356 |
0.329 |
|
| 2011 |
Dickmann LJ, Patel SK, Rock DA, Wienkers LC, Slatter JG. Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 39: 1415-22. PMID 21555507 DOI: 10.1124/Dmd.111.038679 |
0.337 |
|
| 2010 |
Tay S, Dickmann L, Dixit V, Isoherranen N. A comparison of the roles of peroxisome proliferator-activated receptor and retinoic acid receptor on CYP26 regulation. Molecular Pharmacology. 77: 218-27. PMID 19884280 DOI: 10.1124/Mol.109.059071 |
0.371 |
|
| 2009 |
Lutz JD, Dixit V, Yeung CK, Dickmann LJ, Zelter A, Thatcher JE, Nelson WL, Isoherranen N. Expression and functional characterization of cytochrome P450 26A1, a retinoic acid hydroxylase. Biochemical Pharmacology. 77: 258-68. PMID 18992717 DOI: 10.1016/J.Bcp.2008.10.012 |
0.537 |
|
| 2008 |
Tai G, Dickmann LJ, Matovic N, DeVoss JJ, Gillam EM, Rettie AE. Re-engineering of CYP2C9 to probe acid-base substrate selectivity. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 36: 1992-7. PMID 18606741 DOI: 10.1124/Dmd.108.022186 |
0.631 |
|
| 2008 |
McLaughlin LA, Dickmann LJ, Wolf CR, Henderson CJ. Functional expression and comparative characterization of nine murine cytochromes P450 by fluorescent inhibition screening. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 36: 1322-31. PMID 18420780 DOI: 10.1124/Dmd.108.021261 |
0.387 |
|
| 2008 |
Dickmann LJ, Tay S, Senn TD, Zhang H, Visone A, Unadkat JD, Hebert MF, Isoherranen N. Changes in maternal liver Cyp2c and Cyp2d expression and activity during rat pregnancy. Biochemical Pharmacology. 75: 1677-87. PMID 18342837 DOI: 10.1016/J.Bcp.2008.01.012 |
0.339 |
|
| 2008 |
Foti RS, Dickmann LJ, Davis JA, Greene RJ, Hill JJ, Howard ML, Pearson JT, Rock DA, Tay JC, Wahlstrom JL, Slatter JG. Metabolism and related human risk factors for hepatic damage by usnic acid containing nutritional supplements. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 38: 264-80. PMID 18274956 DOI: 10.1080/00498250701802514 |
0.404 |
|
| 2007 |
Pearson JT, Wahlstrom JL, Dickmann LJ, Kumar S, Halpert JR, Wienkers LC, Foti RS, Rock DA. Differential time-dependent inactivation of P450 3A4 and P450 3A5 by raloxifene: a key role for C239 in quenching reactive intermediates. Chemical Research in Toxicology. 20: 1778-86. PMID 18001057 DOI: 10.1021/Tx700207U |
0.306 |
|
| 2007 |
Ribes V, Otto DM, Dickmann L, Schmidt K, Schuhbaur B, Henderson C, Blomhoff R, Wolf CR, Tickle C, Dollé P. Rescue of cytochrome P450 oxidoreductase (Por) mouse mutants reveals functions in vasculogenesis, brain and limb patterning linked to retinoic acid homeostasis. Developmental Biology. 303: 66-81. PMID 17126317 DOI: 10.1016/J.Ydbio.2006.10.032 |
0.323 |
|
| 2004 |
Hummel MA, Dickmann LJ, Rettie AE, Haining RL, Tracy TS. Differential activation of CYP2C9 variants by dapsone. Biochemical Pharmacology. 67: 1831-41. PMID 15130760 DOI: 10.1016/J.Bcp.2004.01.017 |
0.592 |
|
| 2004 |
Redman AR, Dickmann LJ, Kidd RS, Goldstein JA, Ritchie DM, Hon YY. CYP2C9 genetic polymorphisms and warfarin. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 10: 149-54. PMID 15094935 DOI: 10.1177/107602960401000205 |
0.302 |
|
| 2004 |
Dickmann LJ, Locuson CW, Jones JP, Rettie AE. Differential roles of Arg97, Asp293, and Arg108 in enzyme stability and substrate specificity of CYP2C9. Molecular Pharmacology. 65: 842-50. PMID 15044613 DOI: 10.1124/Mol.65.4.842 |
0.588 |
|
| 2002 |
Tracy TS, Hutzler JM, Haining RL, Rettie AE, Hummel MA, Dickmann LJ. Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 30: 385-90. PMID 11901091 DOI: 10.1124/Dmd.30.4.385 |
0.596 |
|
| 2001 |
Dickmann LJ, Rettie AE, Kneller MB, Kim RB, Wood AJ, Stein CM, Wilkinson GR, Schwarz UI. Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Molecular Pharmacology. 60: 382-7. PMID 11455026 DOI: 10.1124/Mol.60.2.382 |
0.558 |
|
| 2001 |
Kim JS, Nafziger AN, Gaedigk A, Dickmann LJ, Rettie AE, Bertino JS. Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe. Journal of Clinical Pharmacology. 41: 715-22. PMID 11452703 DOI: 10.1177/00912700122010618 |
0.501 |
|
| Show low-probability matches. |